- Home
- ANAB vs SHLS Comparison
ANAB vs SHLS Comparison
Compare ANAB & SHLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- SHLS
- Stock Information
- Founded
- ANAB 2005
- SHLS 1996
- Country
- ANAB United States
- SHLS United States
- Employees
- ANAB N/A
- SHLS N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- SHLS Semiconductors
- Sector
- ANAB Health Care
- SHLS Technology
- Exchange
- ANAB Nasdaq
- SHLS Nasdaq
- Market Cap
- ANAB 759.5M
- SHLS 850.9M
- IPO Year
- ANAB 2017
- SHLS 2021
- Fundamental
- Price
- ANAB $22.23
- SHLS $4.72
- Analyst Decision
- ANAB Buy
- SHLS Buy
- Analyst Count
- ANAB 10
- SHLS 24
- Target Price
- ANAB $42.25
- SHLS $9.10
- AVG Volume (30 Days)
- ANAB 559.5K
- SHLS 9.2M
- Earning Date
- ANAB 05-05-2025
- SHLS 05-06-2025
- Dividend Yield
- ANAB N/A
- SHLS N/A
- EPS Growth
- ANAB N/A
- SHLS N/A
- EPS
- ANAB N/A
- SHLS 0.11
- Revenue
- ANAB $111,872,000.00
- SHLS $388,762,000.00
- Revenue This Year
- ANAB N/A
- SHLS $11.24
- Revenue Next Year
- ANAB $9.72
- SHLS $11.79
- P/E Ratio
- ANAB N/A
- SHLS $43.47
- Revenue Growth
- ANAB 387.20
- SHLS N/A
- 52 Week Low
- ANAB $12.21
- SHLS $2.71
- 52 Week High
- ANAB $41.31
- SHLS $8.52
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- SHLS 54.35
- Support Level
- ANAB $20.50
- SHLS $4.28
- Resistance Level
- ANAB $22.84
- SHLS $4.78
- Average True Range (ATR)
- ANAB 1.28
- SHLS 0.42
- MACD
- ANAB 0.12
- SHLS -0.10
- Stochastic Oscillator
- ANAB 83.24
- SHLS 34.40
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.